{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:48:21Z","timestamp":1773298101298,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.neuropharm.2005.01.023","type":"journal-article","created":{"date-parts":[[2005,4,27]],"date-time":"2005-04-27T11:41:22Z","timestamp":1114602082000},"page":"1117-1129","source":"Crossref","is-referenced-by-count":33,"title":["Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB1 and unidentified receptors"],"prefix":"10.1016","volume":"48","author":[{"given":"Ester","family":"Fride","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Datta","family":"Ponde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviva","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lumir","family":"Hanu\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2005.01.023_bib1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-2999(02)01369-9","article-title":"Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)\/CB(2) receptors","volume":"439","author":"Brooks","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib3","first-page":"R7","article-title":"Inhibition of intestinal motility by anandamide, an endogenous cannabinoid","volume":"340","author":"Calignano","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bjp.0704339","article-title":"Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice","volume":"134","author":"Capasso","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0014-2999(02)02830-3","article-title":"Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract","volume":"459","author":"Casu","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1476-5381.1973.tb08534.x","article-title":"The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice","volume":"49","author":"Chesher","year":"1973","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib7","first-page":"586","article-title":"In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity","volume":"277","author":"Compton","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/eoid.12.1.39.21246","article-title":"Cannabinoids for gastrointestinal diseases: potential therapeutic applications","volume":"12","author":"DiCarlo","year":"2003","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(93)90468-W","article-title":"Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent","volume":"231","author":"Fride","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-8993(95)00790-W","article-title":"Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol","volume":"697","author":"Fride","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1054\/plef.2001.0360","article-title":"Endocannabinoids in the central nervous system \u2013 an overview","volume":"66","author":"Fride","year":"2002","journal-title":"Prostagl. Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1300\/J175v02n01_03","article-title":"Cannabinoids and cystic fibrosis: a novel approach to etiology and therapy","volume":"2","author":"Fride","year":"2002","journal-title":"Journal of Cannabis Therapeutics"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib13","series-title":"The biology of marijuana","first-page":"174","article-title":"Cannabinoids and endocannabinoids: behavioral and developmental aspects","author":"Fride","year":"2002"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejphar.2004.10.049","article-title":"(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only","author":"Fride","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Galiegue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib16","first-page":"40","article-title":"The effect of some selective agonists and antagonists on peripheral muscarinic receptors","author":"Gardner","year":"1988","journal-title":"Trends Pharmacol. Sci. Suppl."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-2999(97)01336-8","article-title":"Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals","volume":"339","author":"Griffin","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0922-4106(94)90220-8","article-title":"Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands","volume":"267","author":"Gurwitz","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0165-6147(90)90126-S","article-title":"Novel anxiolytics that act as partial agonists at benzodiazepine receptors","volume":"11","author":"Haefely","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib20","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","article-title":"HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor","volume":"96","author":"Hanus","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00004836-200403000-00005","article-title":"Metabolic bone disease in inflammatory bowel disease","volume":"38","author":"Harpavat","year":"2004","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003495-200464020-00002","article-title":"Management of osteoporosis in adults with cystic fibrosis","volume":"64","author":"Hecker","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib23","series-title":"Cannabinoid receptors","first-page":"145","article-title":"Localization of cannabinoid receptors in brain and periphery","author":"Herkenham","year":"1995"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/PL00005325","article-title":"Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors","volume":"359","author":"Izzo","year":"1999","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(99)00673-1","article-title":"The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats","volume":"384","author":"Izzo","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib26","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.bjp.0703265","article-title":"Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil","volume":"129","author":"Izzo","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib27","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/sj.bjp.0703975","article-title":"Effect of vanilloid drugs on gastrointestinal transit in mice","volume":"132","author":"Izzo","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0016-5085(03)00892-8","article-title":"An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice","volume":"125","author":"Izzo","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib29","doi-asserted-by":"crossref","first-page":"14136","DOI":"10.1073\/pnas.96.24.14136","article-title":"Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors","volume":"96","author":"Jarai","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-2999(02)02053-8","article-title":"Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors","volume":"450","author":"Landi","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib31","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.1073\/pnas.160105897","article-title":"The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis","volume":"97","author":"Malfait","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0091-3057(91)90349-7","article-title":"Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs","volume":"40","author":"Martin","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib33","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/sj.bjp.0705889","article-title":"Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats","volume":"142","author":"Mathison","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1124\/jpet.102.043893","article-title":"Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1)","volume":"304","author":"McVey","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib35","series-title":"Cannabinoid receptors","first-page":"233","article-title":"The unpaved road to the endogenous brain cannabinoid ligands, the anandamides","author":"Mechoulam","year":"1995"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0079-6468(08)70037-7","article-title":"Towards cannabinoid drugs\u2013revisited","volume":"35","author":"Mechoulam","year":"1998","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/syn.20050","article-title":"Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study","volume":"53","author":"Nunez","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib38","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00001756-200204160-00006","article-title":"Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats","volume":"13","author":"Parker","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib40","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/gut.48.6.859","article-title":"Cannabinoids and the gastrointestinal tract","volume":"48","author":"Pertwee","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(02)02624-9","article-title":"(\u2212)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens","volume":"456","author":"Pertwee","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1054\/plef.2001.0345","article-title":"Endocannabinoids and the gut","volume":"66","author":"Pinto","year":"2002","journal-title":"Prostagl. Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1192\/bjp.178.2.107","article-title":"Therapeutic aspects of cannabis and cannabinoids","volume":"178","author":"Robson","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2005.01.023_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1054\/clnu.1999.0080","article-title":"Nutrition and lung function in cystic fibrosis patients: review","volume":"19","author":"Schoni","year":"2000","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib45","first-page":"989","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0091-3057(97)00422-X","article-title":"Biphasic effects of anandamide","volume":"59","author":"Sulcova","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib47","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib48","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/1523-1747.ep12260709","article-title":"The mouse ear inflammatory response to topical arachidonic acid","volume":"82","author":"Young","year":"1984","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.neuropharm.2005.01.023_bib49","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1046\/j.1460-9568.2003.02704.x","article-title":"Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models","volume":"17","author":"Zhang","year":"2003","journal-title":"Eur. J. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390805000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390805000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T15:14:35Z","timestamp":1550243675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390805000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0028390805000638"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2005.01.023","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}